EUVIMEDEUVIMED entdecken
Crossref

Trofinetide Receives FDA Approval as First Drug for Rett Syndrome

Emily Harris

JAMA · 2023

DOI: 10.1001/jama.2023.4003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: Drug Approval, Rett Syndrome, Central Nervous System Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalRett SyndromeCentral Nervous System AgentsHumansGlutamatesUnited States Food and Drug AdministrationUnited States

Substanzen

GlutamatestrofinetideCentral Nervous System Agents

Zitieren

APA

Harris, E. (2023). Trofinetide Receives FDA Approval as First Drug for Rett Syndrome. JAMA. https://doi.org/10.1001/jama.2023.4003

Vancouver

Harris E. Trofinetide Receives FDA Approval as First Drug for Rett Syndrome. JAMA. 2023. doi:10.1001/jama.2023.4003

BibTeX
@article{Harris2023,
  author = {Harris, Emily},
  title = {Trofinetide Receives FDA Approval as First Drug for Rett Syndrome},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2023.4003}
}
Kostenlos starten →